Moderna surges after FDA reverses course on flu vaccine review
Regulatory agency will review mRNA-1010 after surprise about-face, PDUFA set for August 2026
Moderna shares jumped 4% on Wednesday after the US Food and Drug Administration reversed an earlier decision and agreed to review the company's mRNA-1010 seasonal influenza vaccine, breathing new life into a program that investors had written off earlier this month.
The FDA's surprise reversal comes less than two weeks after the regulatory agency initially refused to file Moderna's biologics license application for the flu vaccine, triggering a 12% plunge in the biotechnology company's stock on February 3rd. The sudden about-face marks a dramatic shift in fortunes for Moderna's most advanced program outside its COVID-19 franchise.
According to the Washington Post, the FDA will now conduct a full review of mRNA-1010 with a decision goal date of August 5, 2026. The agency has indicated it will consider full approval for adults aged 50-64 and accelerated approval for those 65 and older, contingent on a post-marketing study commitment to validate effectiveness in older populations.
The regulatory restart opens a path for mRNA-1010 to potentially reach the market in time for the 2026-2027 flu season, a critical timeline for a company seeking to diversify beyond its COVID-19 vaccine franchise. Moderna's revenue has declined sharply since the pandemic's peak, with trailing twelve-month sales falling to $1.94 billion, down 29.8% year-over-year as reported in the most recent quarterly earnings.
Moderna's stock closed at $43.93, up $1.70 on the day, but remains well below its 52-week high of $55.20. The Cambridge, Massachusetts-based company now commands a market capitalization of $16.5 billion, reflecting investor skepticism about its pipeline progression outside of COVID-19. Analysts have an average target price of $40.90 on the shares, according to current consensus data.
The mRNA-1010 vaccine represents Moderna's flagship effort to demonstrate that its messenger RNA technology can succeed beyond COVID-19. Traditional flu vaccines, typically produced in chicken eggs, take approximately six months to manufacture. Moderna's mRNA platform promises faster production and potentially better matching of circulating flu strains—a value proposition the company hopes will differentiate it in a crowded seasonal vaccine market.
Seasonal influenza generates approximately $8 billion in annual global vaccine sales, dominated by established players including Sanofi, GlaxoSmithKline, and Seqirus. These competitors have decades of manufacturing experience and well-established distribution relationships with healthcare providers and pharmacies. Moderna will need to demonstrate clear advantages in efficacy, speed, or manufacturing flexibility to capture meaningful market share.
The FDA's initial refusal to file mRNA-1010 had raised concerns about the quality of Moderna's application data, particularly regarding immunogenicity endpoints across different age groups and flu strains. The regulator's willingness to review the application after additional discussions suggests those concerns may have been addressed through supplementary data or revised clinical trial analysis plans.
Analyst sentiment on Moderna remains mixed. Of 24 analysts covering the stock, three rate it a buy, 18 maintain a hold rating, and three recommend selling, according to current data. The stock trades at 32.47 times forward earnings estimates, reflecting expectations that the company must successfully develop new products to justify its valuation after COVID-19 vaccine demand normalized.
The August 5, 2026 PDUFA date provides investors with a clear catalyst to watch, though the regulatory timeline remains lengthy. The accelerated approval pathway for adults 65 and older could allow Moderna to capture this higher-risk demographic more quickly, given that older adults typically account for the majority of flu-related hospitalizations and deaths.
Moderna's broader pipeline includes candidates against respiratory syncytial virus, cytomegalovirus, and cancer vaccines, but the flu program represents the nearest-term opportunity for meaningful new revenue. The company reported negative earnings per share of $7.26 over the trailing twelve months, underscoring the urgency of bringing new products to market as it continues investing heavily in research and development.
The FDA's decision removes a significant overhang on the stock that had persisted since early February, but investors will be watching closely for clinical data readouts and regulatory progress throughout 2026. Success with mRNA-1010 would validate Moderna's platform beyond COVID-19 and potentially open doors to additional applications of the technology in preventive vaccines.